Bicara Therapeutics Inc. 8-K

What Happened
Bicara Therapeutics Inc. announced the results of its 2026 annual meeting of stockholders held on June 9, 2026. Of 65,600,370 shares outstanding as of the record date, 55,924,987 shares (about 85.25%) were present or represented. Stockholders elected Christopher Bowden, M.D. and Carolyn Ng, Ph.D. as Class II directors for three-year terms, and ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The 8-K was filed June 10, 2026 and signed by CEO Claire Mazumdar, Ph.D.

Key Details

• Total shares outstanding (record date): 65,600,370; shares present/represented: 55,924,987 (≈85.25%).
• Director votes: Christopher Bowden — 48,558,710 for; 5,145,418 withheld; 2,220,859 broker non-votes. Carolyn Ng — 47,431,269 for; 6,272,859 withheld; 2,220,859 broker non-votes.
• Auditor ratification: KPMG LLP ratified with 55,914,602 votes for, 8,815 against, 1,570 abstaining.
• No other matters were submitted or voted on at the meeting.

Why It Matters
Board elections and auditor ratification are routine but material governance items for investors: the re-election of two Class II directors maintains board continuity and oversight, while ratifying KPMG confirms the auditor that will review Bicara’s 2026 financial statements. Voting tallies (including withheld votes and broker non-votes) show the level of shareholder participation and any shareholder dissent on director elections, which investors may monitor for governance trends.